Core Viewpoint - Rosen Law Firm is reminding investors who purchased NAPCO Security Technologies, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on June 24, 2025 [1]. Group 1: Class Action Details - Investors who purchased NAPCO securities between February 5, 2024, and February 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by June 24, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that NAPCO made false and misleading statements regarding its revenue outlook and growth potential, downplaying risks associated with seasonality and macroeconomic factors [5]. - It is claimed that NAPCO's optimistic margin growth goals were unrealistic, as the company was not adequately prepared to forecast demand for its products [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Organon & Co. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the Organon securities lawsuit is from October 31, 2024, to April 30, 2025, inclusive [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by July 22, 2025 [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [3]. Group 3: Case Allegations - The lawsuit alleges that Organon's defendants made misleading statements about the company's priorities, particularly regarding capital allocation and quarterly dividends [4]. - It is claimed that the defendants concealed the importance of Organon's debt reduction strategy following the acquisition of Dermavant, which led to a 70% decrease in the regular quarterly dividend [4]. - The lawsuit asserts that investors suffered damages when the true details about the company's financial situation became public [4].

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”), of the important July 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Iovance securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Everus Construction Group, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the lawsuit is defined as between October 31, 2024, and February 11, 2025, inclusive [1]. - Investors who held MDU Resources common stock as of October 21, 2024, and acquired Everus Construction common stock during the spinoff may be eligible for compensation [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 3, 2025 [3]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [4]. - Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered substantial amounts for investors [4]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, defendants made false or misleading statements regarding Everus Construction's business operations [5]. - Specific claims include that the backlog conversion cycle had elongated due to larger projects, leading to delayed revenue recognition [5]. - The lawsuit asserts that the positive statements made by defendants were materially misleading and lacked a reasonable basis [5].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Organon & Co. securities for the period between October 31, 2024, and April 30, 2025, due to misleading statements regarding the company's capital allocation and dividend strategy [1][5]. Group 1: Lawsuit Details - The lawsuit alleges that Organon provided positive statements while concealing material adverse facts about its priorities, particularly regarding capital allocation and a significant reduction in quarterly dividends [5]. - Following the acquisition of Dermavant, Organon prioritized debt reduction, leading to a 70% decrease in the regular quarterly dividend, which was not disclosed to investors [5]. Group 2: Participation Information - Investors who purchased Organon securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A class action lawsuit has been filed against Krispy Kreme, Inc. for misleading statements regarding its partnership with McDonald's and the subsequent decline in product demand, with a lead plaintiff deadline set for July 15, 2025 [1][4]. Group 1: Lawsuit Details - The lawsuit alleges that Krispy Kreme made false and misleading statements about the demand for its products at McDonald's locations, which materially declined after the initial marketing launch [4]. - It is claimed that the declining demand at McDonald's was a significant factor in the decrease of average sales per door per week [4]. - The partnership with McDonald's is stated to have been unprofitable, posing risks to its continuation and leading to a pause in expansion into new locations [4]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [3]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [3]. Group 3: Participation Information - Investors who purchased Krispy Kreme securities during the class period may be entitled to compensation without upfront fees through a contingency fee arrangement [1]. - To join the class action, investors can submit a form or contact the Rosen Law Firm for more information [2][5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Open Lending Corporation securities during the specified class period of the upcoming lead plaintiff deadline on June 30, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Open Lending securities between February 24, 2022, and March 31, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by June 30, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Open Lending - The lawsuit alleges that Open Lending's defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and operations [5]. - Specific allegations include misrepresentation of Open Lending's risk-based pricing models, misleading statements regarding profit share revenue, and failure to disclose the devaluation of vintage loans from 2021 and 2022 [5]. - The lawsuit claims that these misleading statements resulted in investor damages when the true details became public [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of West Pharmaceutical Services, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 7, 2025 [1]. Group 1: Class Action Details - Investors who bought West common stock between February 16, 2023, and February 12, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lead plaintiff must file a motion with the Court by July 7, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has been ranked highly for its performance in this area [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]. Group 3: Case Allegations - The lawsuit alleges that West Pharmaceutical Services made false and misleading statements regarding its business operations, particularly concerning its High-Value Products portfolio and the SmartDose device [5]. - It is claimed that West was experiencing significant destocking and operational inefficiencies that were not disclosed, leading to misleading positive statements about the company's prospects [5]. - The lawsuit asserts that these undisclosed issues resulted in damages to investors when the true situation became known [5].

Core Viewpoint - Rosen Law Firm is reminding investors of Zenas BioPharma, Inc. about a class action lawsuit related to the company's IPO, with a lead plaintiff deadline set for June 16, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased Zenas BioPharma securities may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lawsuit alleges that the Registration Statement contained false or misleading statements regarding the company's financial sustainability and operations funding [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company at the time [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Digimarc Corporation during the specified class period of the upcoming lead plaintiff deadline on July 8, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Digimarc securities between May 3, 2024, and February 26, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by July 8, 2025 [2]. - The lawsuit alleges that Digimarc made false and misleading statements regarding its business operations and revenue, which led to investor damages when the truth was revealed [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3].